| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3047e7491266498fd3469fa668831e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac7679db593a81201a85741a4a27e959 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55538 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2013-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_092766c41caf7334984d0adf6b531b58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29f636a8e7984e92b54e620db28a2dfa |
| publicationDate |
2014-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014056931-A1 |
| titleOfInvention |
Genetic adjuvants for immunotherapy |
| abstract |
The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions of the invention contain nucleic acid molecules encoding IL-12 and/or IFN-γ and an operably-linked promoter sequence. In another aspect, the present invention concerns expression vectors containing a nucleotide sequence encoding IL-12 and IFN-γ, and an operably-linked promoter sequence. In another aspect, the present invention concerns cells genetically modified with a nucleotide sequence encoding IL-12 and IFN-γ. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10646549-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11571463-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11311602-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11421011-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11000573-B2 |
| priorityDate |
2002-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |